Abstract

Hematopoietic stem and progenitor cells (HSPCs) originate from an endothelial-to-hematopoietic transition (EHT) during embryogenesis. Characterization of early hemogenic endothelial (HE) cells is required to understand what drives hemogenic specification and to accurately define cells capable of undergoing EHT. Using Cellular Indexing of Transcriptomes and Epitopes by Sequencing (CITE-seq), we define the early subpopulation of pre-HE cells based on both surface markers and transcriptomes. We identify the transcription factor Meis1 as an essential regulator of hemogenic cell specification in the embryo prior to Runx1 expression. Meis1 is expressed at the earliest stages of EHT and distinguishes pre-HE cells primed towards the hemogenic trajectory from the arterial endothelial cells that continue towards a vascular fate. Endothelial-specific deletion of Meis1 impairs the formation of functional Runx1-expressing HE which significantly impedes the emergence of pre-HSPC via EHT. Our findings implicate Meis1 in a critical fate-determining step for establishing EHT potential in endothelial cells.

Hematopoietic stem cell formation via the endothelial-to-hematopoietic transition is initiated by a complex rewiring of the aortic endothelium. Here the authors identify Meis1 as an early driver of hemogenic specification of this arterial endothelium.

Details

Title
Meis1 establishes the pre-hemogenic endothelial state prior to Runx1 expression
Author
Coulombe, Patrick 1   VIAFID ORCID Logo  ; Cole, Grace 2 ; Fentiman, Amanda 3 ; Parker, Jeremy D. K. 4 ; Yung, Eric 5   VIAFID ORCID Logo  ; Bilenky, Misha 4 ; Degefie, Lemlem 4   VIAFID ORCID Logo  ; Lac, Patrick 4 ; Ling, Maggie Y. M. 4   VIAFID ORCID Logo  ; Tam, Derek 4 ; Humphries, R. Keith 6 ; Karsan, Aly 7   VIAFID ORCID Logo 

 BC Cancer, Michael Smith Genome Sciences Centre, Vancouver, Canada (GRID:grid.434706.2) (ISNI:0000 0004 0410 5424); University of British Columbia, Department of Experimental Medicine, Vancouver, Canada (GRID:grid.17091.3e) (ISNI:0000 0001 2288 9830) 
 BC Cancer, Michael Smith Genome Sciences Centre, Vancouver, Canada (GRID:grid.434706.2) (ISNI:0000 0004 0410 5424); University of British Columbia, Department of Pathology and Laboratory Medicine, Vancouver, Canada (GRID:grid.17091.3e) (ISNI:0000 0001 2288 9830) 
 BC Cancer, Michael Smith Genome Sciences Centre, Vancouver, Canada (GRID:grid.434706.2) (ISNI:0000 0004 0410 5424); University of British Columbia, Interdisciplinary Oncology Program, Vancouver, Canada (GRID:grid.17091.3e) (ISNI:0000 0001 2288 9830) 
 BC Cancer, Michael Smith Genome Sciences Centre, Vancouver, Canada (GRID:grid.434706.2) (ISNI:0000 0004 0410 5424) 
 BC Cancer, Terry Fox Laboratory, Vancouver, Canada (GRID:grid.248762.d) (ISNI:0000 0001 0702 3000) 
 BC Cancer, Terry Fox Laboratory, Vancouver, Canada (GRID:grid.248762.d) (ISNI:0000 0001 0702 3000); University of British Columbia, Department of Medical Genetics, Vancouver, Canada (GRID:grid.17091.3e) (ISNI:0000 0001 2288 9830) 
 BC Cancer, Michael Smith Genome Sciences Centre, Vancouver, Canada (GRID:grid.434706.2) (ISNI:0000 0004 0410 5424); University of British Columbia, Department of Experimental Medicine, Vancouver, Canada (GRID:grid.17091.3e) (ISNI:0000 0001 2288 9830); University of British Columbia, Department of Pathology and Laboratory Medicine, Vancouver, Canada (GRID:grid.17091.3e) (ISNI:0000 0001 2288 9830); University of British Columbia, Interdisciplinary Oncology Program, Vancouver, Canada (GRID:grid.17091.3e) (ISNI:0000 0001 2288 9830) 
Pages
4537
Publication year
2023
Publication date
2023
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2842707147
Copyright
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.